Literature DB >> 12124982

Human cell lines engineered for tetracycline-regulated expression of tumor suppressor candidate genes from a frequently affected chromosomal region, 3p21.

Alexei I Protopopov1, Jinfeng Li, Gösta Winberg, Rinat Z Gizatullin, Vladimir I Kashuba, George Klein, Eugene R Zabarovsky.   

Abstract

BACKGROUND: We modified a tetracycline-regulated system that can control the activity of individual genes quantitatively and reversibly in transgenic mammals. Despite these advances, there remained one problem in the intensive use of the tet-system: the limited range of acceptor cell lines, expressing a tetracycline-controlled transcriptional activator (tTA). This study describes in detail new vectors and a unifying strategy to generate tTA-expressing cell lines.
METHOD: Two retroviral vectors pLNCtTA-hCMV and pLNCtTA-EF1alpha coding for the tTA were used to engineer cell lines to constitutively express tTA. New expression vectors pETE-Hyg and pETE-Bsd were also created that replicate in episomal form in human cells and facilitate tetracycline-regulated expression of targeted genes.
RESULTS: The primate-tropic retroviruses efficiently delivered the regulatory tTA gene into 12 selected human cancer cell lines. Two candidate tumor suppressor genes from the human 3p21-p22 region MAPKAPK3 (3pK) and MLH1 were cloned into the episomal vector and transfected into engineered A9 and KRC/Y cells. The transfectants were subcutaneously grown in SCID mice, and the expression of the transgene was successfully controlled in vivo by tetracycline administered ad libitum in drinking water. The experiments demonstrated that both transgenes did not antagonize the tumorous growth of these cells.
CONCLUSIONS: New retroviral and episomal vectors appear particularly suited for tight regulation of genes that cause suppression of cell growth. The generated cell lines can be used in various applications to study the effect of an inducible transgene in human cancer cells. Copyright 2002 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12124982     DOI: 10.1002/jgm.283

Source DB:  PubMed          Journal:  J Gene Med        ISSN: 1099-498X            Impact factor:   4.565


  23 in total

1.  Novel lentiviral-inducible transgene expression systems and versatile single-plasmid reporters for in vitro and in vivo cancer biology studies.

Authors:  W H Shuen; R Kan; Z Yu; H L Lung; M L Lung
Journal:  Cancer Gene Ther       Date:  2015-02-27       Impact factor: 5.987

2.  A novel crosstalk between the tumor suppressors ING1 and ING2 regulates androgen receptor signaling.

Authors:  Mohsen Esmaeili; Thanakorn Pungsrinont; Andrea Schaefer; Aria Baniahmad
Journal:  J Mol Med (Berl)       Date:  2016-06-16       Impact factor: 4.599

3.  Chromosome 14 transfer and functional studies identify a candidate tumor suppressor gene, mirror image polydactyly 1, in nasopharyngeal carcinoma.

Authors:  Arthur Kwok Leung Cheung; Hong Lok Lung; Josephine Mun Yee Ko; Yue Cheng; Eric J Stanbridge; Eugene R Zabarovsky; John M Nicholls; Daniel Chua; Sai Wah Tsao; Xin-Yuan Guan; Maria Li Lung
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-10       Impact factor: 11.205

4.  Extracellular protease ADAMTS9 suppresses esophageal and nasopharyngeal carcinoma tumor formation by inhibiting angiogenesis.

Authors:  Paulisally Hau Yi Lo; Hong Lok Lung; Arthur Kwok Leung Cheung; Suneel S Apte; Kwok Wah Chan; Fung Mei Kwong; Josephine Mun Yee Ko; Yue Cheng; Simon Law; Gopesh Srivastava; Eugene R Zabarovsky; Sai Wah Tsao; Johnny Cheuk On Tang; Eric J Stanbridge; Maria Li Lung
Journal:  Cancer Res       Date:  2010-06-15       Impact factor: 12.701

5.  Cysteine-rich intestinal protein 2 (CRIP2) acts as a repressor of NF-kappaB-mediated proangiogenic cytokine transcription to suppress tumorigenesis and angiogenesis.

Authors:  Arthur Kwok Leung Cheung; Josephine M Y Ko; Hong Lok Lung; Kwok Wah Chan; Eric J Stanbridge; Eugene Zabarovsky; Takashi Tokino; Lisa Kashima; Toshiharu Suzuki; Dora Lai-Wan Kwong; Daniel Chua; Sai Wah Tsao; Maria Li Lung
Journal:  Proc Natl Acad Sci U S A       Date:  2011-05-03       Impact factor: 11.205

6.  NBBS isolated from Pygeum africanum bark exhibits androgen antagonistic activity, inhibits AR nuclear translocation and prostate cancer cell growth.

Authors:  Maria Papaioannou; Sonja Schleich; Daniela Roell; Undine Schubert; Tamzin Tanner; Frank Claessens; Rudolf Matusch; Aria Baniahmad
Journal:  Invest New Drugs       Date:  2009-09-23       Impact factor: 3.850

7.  Androgens induce a distinct response of epithelial-mesenchymal transition factors in human prostate cancer cells.

Authors:  Juliane Colditz; Benjamin Rupf; Caroline Maiwald; Aria Baniahmad
Journal:  Mol Cell Biochem       Date:  2016-08-25       Impact factor: 3.396

8.  Simultaneous down-regulation of tumor suppressor genes RBSP3/CTDSPL, NPRL2/G21 and RASSF1A in primary non-small cell lung cancer.

Authors:  Vera N Senchenko; Ekaterina A Anedchenko; Tatiana T Kondratieva; George S Krasnov; Alexei A Dmitriev; Veronika I Zabarovska; Tatiana V Pavlova; Vladimir I Kashuba; Michael I Lerman; Eugene R Zabarovsky
Journal:  BMC Cancer       Date:  2010-03-01       Impact factor: 4.430

9.  RBSP3 (HYA22) is a tumor suppressor gene implicated in major epithelial malignancies.

Authors:  Vladimir I Kashuba; Jingfeng Li; Fuli Wang; Vera N Senchenko; Alexey Protopopov; Alena Malyukova; Alexey S Kutsenko; Elena Kadyrova; Veronika I Zabarovska; Olga V Muravenko; Alexander V Zelenin; Lev L Kisselev; Igor Kuzmin; John D Minna; Gösta Winberg; Ingemar Ernberg; Eleonora Braga; Michael I Lerman; George Klein; Eugene R Zabarovsky
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-29       Impact factor: 11.205

10.  High mutability of the tumor suppressor genes RASSF1 and RBSP3 (CTDSPL) in cancer.

Authors:  Vladimir I Kashuba; Tatiana V Pavlova; Elvira V Grigorieva; Alexey Kutsenko; Surya Pavan Yenamandra; Jingfeng Li; Fuli Wang; Alexei I Protopopov; Veronika I Zabarovska; Vera Senchenko; Klas Haraldson; Tatiana Eshchenko; Julia Kobliakova; Olga Vorontsova; Igor Kuzmin; Eleonora Braga; Vladimir M Blinov; Lev L Kisselev; Yi-Xin Zeng; Ingemar Ernberg; Michael I Lerman; George Klein; Eugene R Zabarovsky
Journal:  PLoS One       Date:  2009-05-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.